A Phase II, Multicentric, Prospective, Non-comparative Clinical Trial to Assess the Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency (PDH) Patients With Glycerol Phenybutyrate (RAVICTI)
Latest Information Update: 20 Jan 2026
At a glance
- Drugs Glycerol phenylbutyrate (Primary)
- Indications Pyruvate dehydrogenase complex deficiency disease
- Focus Therapeutic Use
- Acronyms PDH-RAVICTI
Most Recent Events
- 15 Jan 2026 Planned End Date changed from 1 Dec 2026 to 1 Apr 2027.
- 15 Jan 2026 Planned primary completion date changed from 1 Nov 2025 to 1 Mar 2026.
- 15 Jan 2026 Status changed from not yet recruiting to recruiting.